NCT00101998

Study Of Alvimopan Drug For Treatment Of Constipation Due To Prescription Pain Medication

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase IIb Study to Evaluate the Efficacy and Safety of Multiple Alvimopan Dosage Regimens for the Treatment of Opioid-Induced Bowel Dysfunction in Cancer Pain Subjects

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 233 (actual)
• Sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A multicenter study to evaluate the effectiveness and safety of multiple dosage regimens of an investigational drug for the treatment of constipation due to prescription pain medication in subjects with cancer pain. The study will require five visits over a five-week period.

Conditions

• Constipation
• Bowel Dysfunction

Interventions

Type	Name	Description
DRUG	alvimopan
DRUG	placebo

Timeline

• Start date: 2003-10-01
• Primary completion: 2006-05-01
• Completion: 2006-05-01
• First posted: 2005-01-19
• Last updated: 2017-08-30

Locations

162 sites across 26 countries: United States, Argentina, Australia, Canada, Czechia, Finland, France, Germany, Hong Kong, Hungary, India, Italy, Netherlands, New Zealand, Pakistan, Peru, Philippines, Poland, Portugal, Russia, South Africa, South Korea, Spain, Taiwan, Thailand, United Kingdom